UP
Cytochrome P450 : Alphabetical drug list
L
NEXT
Quick Links:
1A2 2C9 2C19 2D6 2E1 3A4
 
Have you read our disclaimer?
L
Drug CYP interaction Clinical consequences
labetalol 2D6 : metabolism, ? inhibits interaction potential eg. with imipramine
lansoprazole (Proton pump inhibitor) - low risk of interactions CYP1A2 (? induces) NO effect on theophylline metabolism
CYP3A4 : metabolism ?
CYP2C19 : metabolism ?
2C19 : INHIBITS (Ki 3 µmol) ?
2D6 : inhibits (Ki 45 µmol) ?
lercanidipine ! 3A4 : metabolism ?
levetiracetam - probably NOT a CYP inhibitor - Nil
levomepromazine ? 2D6 : INHIBITS of questionable clinical significance [Int J Clin Pharmacol Ther 1995 Dec;33(12):646-52] but increases bromperidol levels, and may inhibit codeine effect
lidocaine : See lignocaine
lignocaine (=lidocaine) 1A2 : METABOLISM (may be most important at clinical levels!) [Pharmacol Toxicol 1999 Nov;85(5):201-5] ?
CYP3A4 : metabolism to MEGX (monoethylglycinexylidide) - NOT a good test of 3A4 activity [Br J Clin Pharmacol 1998 Dec;46(6):535-9] ? erythromycin, itraconazole may increase levels; rifampicin induces metabolism
2D6 : metabolism ! ?
1A2 : mild inhibition ?
loratadine (non-sedating anti-histamine : appears to lack cardiac toxicity) 3A4 : inhibits (IC50 32 µM) ?
2C19 : INHIBITS (Ki 0.17 µM) ?
2D6 : metabolism ?
3A4 : metabolism ?; appears safe with e.g. erythromycin
lornoxicam 2C9 : METABOLISM ?
losartan CYP2C9 : ACTIVATION ? potential for less effect with 2C9 inhibition (fluconazole, miconazole, sulphamethoxazole)
3A4 : activation [Pharmacotherapy 2000 Feb;20(2):130-9] 2C9 + 3A4 inhibition may be needed if activation is to be affected! [J Clin Pharmacol 1999 Apr;39(4):418-24]
lovastatin (See also HMG Co-A reductase inhibitors) CYP3A4 : METABOLISM
(also 3A5, 3A7)
significant interaction eg. diltiazem massively increases levels [Clin Pharmacol Ther 1998 Oct;64(4):369-77] - rhabdomyolysis
2C9 : INHIBITS ?


Quick Links:
1A2 2C9 2C19 2D6 2E1 3A4
 



Page author: jo@anaesthetist.com Last update: 2000-6-22